EP0659439B1
(en)
|
1993-12-24 |
2001-10-24 |
MERCK PATENT GmbH |
Immunoconjugates
|
US7060808B1
(en)
*
|
1995-06-07 |
2006-06-13 |
Imclone Systems Incorporated |
Humanized anti-EGF receptor monoclonal antibody
|
AU4373197A
(en)
*
|
1996-09-19 |
1998-04-14 |
Diagnocure Inc. |
Recombinant single chain antibodies directed against the gp54 cancer marker, composition comprising same and use thereof
|
DK0942968T3
(da)
*
|
1996-12-03 |
2008-06-23 |
Amgen Fremont Inc |
Fuldt humane antistoffer, der binder EGFR
|
CN1276830A
(zh)
*
|
1997-09-02 |
2000-12-13 |
住友制药株式会社 |
抗乙型肝炎病毒核心蛋白的单链抗体及其基因和含有它们的乙型肝炎治疗药物
|
DE19744531A1
(de)
*
|
1997-10-09 |
1999-05-27 |
Klaus Dr Rer Nat Bosslet |
Bindemoleküle gegen Rezeptor-Ligand-Komplexe
|
DE69841273D1
(de)
|
1997-11-17 |
2009-12-17 |
Micromet Ag |
Verfahren zur identifikation von bindestellendomänen, die ihre epitopbindefähigkeit beibehalten
|
US20030224001A1
(en)
*
|
1998-03-19 |
2003-12-04 |
Goldstein Neil I. |
Antibody and antibody fragments for inhibiting the growth of tumors
|
ZA200007412B
(en)
*
|
1998-05-15 |
2002-03-12 |
Imclone Systems Inc |
Treatment of human tumors with radiation and inhibitors of growth factor receptor tyrosine kinases.
|
ATE217889T1
(de)
|
1998-08-28 |
2002-06-15 |
Genentech Inc |
Humane antikörper gegen faktor ix/ixa
|
EE200100603A
(et)
*
|
1999-05-14 |
2003-02-17 |
Imclone Systems Incorporated |
Inimese refraktaarsete kasvajate ravi epidermaalse kasvufaktori retseptori antagonistidega
|
US7144991B2
(en)
|
1999-06-07 |
2006-12-05 |
Aletheon Pharmaceuticals, Inc. |
Streptavidin expressed gene fusions and methods of use thereof
|
US7361338B2
(en)
*
|
1999-10-05 |
2008-04-22 |
Agensys, Inc. |
Methods to inhibit growth of prostate cancer cells
|
US6790631B1
(en)
*
|
1999-10-05 |
2004-09-14 |
Agensys, Inc. |
G protein-coupled receptor up-regulated in prostate cancer and uses thereof
|
AU2001258567A1
(en)
*
|
2000-05-19 |
2001-11-26 |
Scancell Limited |
Humanised antibodies to the epidermal growth factor receptor
|
EP1314740A4
(en)
*
|
2000-06-14 |
2005-01-19 |
Med & Biological Lab Co Ltd |
PREPARATION METHODS OF FLUORESCENCE PROTEIN FUSIONED SCFV ANTIBODIES
|
US7449308B2
(en)
*
|
2000-06-28 |
2008-11-11 |
Glycofi, Inc. |
Combinatorial DNA library for producing modified N-glycans in lower eukaryotes
|
US8697394B2
(en)
|
2000-06-28 |
2014-04-15 |
Glycofi, Inc. |
Production of modified glycoproteins having multiple antennary structures
|
DK1522590T3
(da)
*
|
2000-06-28 |
2009-12-21 |
Glycofi Inc |
Fremgangsmåde til fremstilling af modificerede glykoproteiner
|
US7598055B2
(en)
*
|
2000-06-28 |
2009-10-06 |
Glycofi, Inc. |
N-acetylglucosaminyltransferase III expression in lower eukaryotes
|
CA2418083A1
(en)
*
|
2000-08-09 |
2002-02-14 |
Imclone Systems Incorporated |
Treatment of hyperproliferative diseases with epidermal growth factor receptor antagonists
|
AU2001288342A1
(en)
*
|
2000-08-21 |
2002-03-04 |
Smith Kline Beecham Corporation |
Anti-rank ligand monoclonal antibodies useful in treatment of rank ligand mediated disorders
|
US20030133939A1
(en)
*
|
2001-01-17 |
2003-07-17 |
Genecraft, Inc. |
Binding domain-immunoglobulin fusion proteins
|
US7829084B2
(en)
*
|
2001-01-17 |
2010-11-09 |
Trubion Pharmaceuticals, Inc. |
Binding constructs and methods for use thereof
|
US7754208B2
(en)
|
2001-01-17 |
2010-07-13 |
Trubion Pharmaceuticals, Inc. |
Binding domain-immunoglobulin fusion proteins
|
CN101684158A
(zh)
*
|
2001-01-17 |
2010-03-31 |
特鲁比昂药品公司 |
结合域-免疫球蛋白融合蛋白
|
GB0103389D0
(en)
*
|
2001-02-12 |
2001-03-28 |
Novartis Ag |
Organic compounds
|
ATE434936T1
(de)
|
2001-03-14 |
2009-07-15 |
Myriad Genetics Inc |
Tsg101-gag-wechselwirkung und ihre verwendung
|
US20080008704A1
(en)
*
|
2001-03-16 |
2008-01-10 |
Mark Rubin |
Methods of treating colorectal cancer with anti-epidermal growth factor antibodies
|
US20100056762A1
(en)
|
2001-05-11 |
2010-03-04 |
Old Lloyd J |
Specific binding proteins and uses thereof
|
PT1392359E
(pt)
|
2001-05-11 |
2010-01-27 |
Ludwig Inst For Cancer Res Ltd |
Proteínas de ligação específica e suas utilizações
|
US20020193569A1
(en)
*
|
2001-06-04 |
2002-12-19 |
Idec Pharmaceuticals Corporation |
Bispecific fusion protein and method of use for enhancing effector cell killing of target cells
|
CN1966525A
(zh)
*
|
2001-06-13 |
2007-05-23 |
根马布股份公司 |
表皮生长因子受体(egfr)的人单克隆抗体
|
US7595378B2
(en)
*
|
2001-06-13 |
2009-09-29 |
Genmab A/S |
Human monoclonal antibodies to epidermal growth factor receptor (EGFR)
|
JP2006506317A
(ja)
|
2002-01-11 |
2006-02-23 |
バイオマリン ファーマシューティカル インコーポレイテッド |
治療用リソソーム酵素の送達のための酵素送達系としてのp97の使用
|
US20050276812A1
(en)
|
2004-06-01 |
2005-12-15 |
Genentech, Inc. |
Antibody-drug conjugates and methods
|
US8034904B2
(en)
*
|
2002-06-14 |
2011-10-11 |
Immunogen Inc. |
Anti-IGF-I receptor antibody
|
HUP0600340A3
(en)
|
2002-07-15 |
2011-06-28 |
Genentech Inc |
Methods for identifying tumors that are responsive to treatment with anti-erbb2 antibodies
|
CN100351260C
(zh)
|
2002-11-12 |
2007-11-28 |
布赖汉姆妇女医院 |
葡萄球菌感染的多糖疫苗
|
US20040147428A1
(en)
*
|
2002-11-15 |
2004-07-29 |
Pluenneke John D. |
Methods of treatment using an inhibitor of epidermal growth factor receptor
|
US7332299B2
(en)
|
2003-02-20 |
2008-02-19 |
Glycofi, Inc. |
Endomannosidases in the modification of glycoproteins in eukaryotes
|
EP1622941A2
(en)
*
|
2003-03-20 |
2006-02-08 |
ImClone Systems Incorporated |
Method of producing an antibody to epidermal growth factor receptor
|
US7754209B2
(en)
|
2003-07-26 |
2010-07-13 |
Trubion Pharmaceuticals |
Binding constructs and methods for use thereof
|
PT1687338E
(pt)
|
2003-11-07 |
2011-01-20 |
Ablynx Nv |
Anticorpos de domínio único vhh de camelídeos direccionados para o receptor do factor de crescimento epidérmico e suas utilizações
|
MXPA06010715A
(es)
*
|
2004-03-19 |
2007-05-23 |
Imclone Systems Inc |
Anticuerpo del receptor del factor de crecimiento humano anti-epidermico.
|
SI1745075T1
(sl)
*
|
2004-04-21 |
2013-07-31 |
The Brigham And Women's Hospital, Inc. |
Poli-N-acetilglukozamin (PNAG/dPNAG) vezavni peptidi in postopki za njihovo uporabo
|
GB0410627D0
(en)
*
|
2004-05-12 |
2004-06-16 |
Scancell Ltd |
Specific binding members
|
US20100111856A1
(en)
|
2004-09-23 |
2010-05-06 |
Herman Gill |
Zirconium-radiolabeled, cysteine engineered antibody conjugates
|
DK1791565T3
(en)
|
2004-09-23 |
2016-08-01 |
Genentech Inc |
Cysteingensplejsede antibodies and conjugates
|
CN105012953B
(zh)
|
2005-07-25 |
2018-06-22 |
阿普泰沃研发有限责任公司 |
用cd37-特异性和cd20-特异性结合分子减少b-细胞
|
AU2006323412A1
(en)
*
|
2005-12-06 |
2007-06-14 |
Domantis Limited |
Ligands that have binding specificity for EGFR and/or VEGF and methods of use therefor
|
US7503217B2
(en)
*
|
2006-01-27 |
2009-03-17 |
Weatherford/Lamb, Inc. |
Sonar sand detection
|
US8173374B2
(en)
|
2006-03-06 |
2012-05-08 |
Agency For Science, Technology And Research |
Human embryonic stem cell methods and PODXL expression
|
RU2487888C2
(ru)
|
2006-06-12 |
2013-07-20 |
ЭМЕРДЖЕНТ ПРОДАКТ ДИВЕЛОПМЕНТ СИЭТЛ, ЭлЭлСи |
Одноцепочечные мультивалентные связывающие белки с эффекторной функцией
|
WO2008007648A1
(fr)
|
2006-07-10 |
2008-01-17 |
Institute For Antibodies Co., Ltd. |
Procédé de classification d'antigène, procédé d'identification d'antigène, procédé d'obtention d' un ensemble d'antigènes ou d'anticorps, procédés de construction d'un panel d'anticorps, anticorps et ens
|
EP2101816B1
(en)
|
2006-12-07 |
2013-08-14 |
Novartis AG |
Antagonist antibodies against ephb3
|
RU2009128237A
(ru)
*
|
2006-12-22 |
2011-01-27 |
Новеликс Терапьютикс Гмбх (At) |
Лечение диабета, по меньшей мере, одним антителом, специфичным к рецептору эпидермального фактора роста, или его производным
|
EP2126127B1
(en)
|
2007-01-25 |
2016-09-28 |
Dana-Farber Cancer Institute, Inc. |
Use of anti-egfr antibodies in treatment of egfr mutant mediated disease
|
US9023356B2
(en)
|
2007-03-15 |
2015-05-05 |
Ludwig Institute For Cancer Research Ltd |
Treatment method using EGFR antibodies and SRC inhibitors and related formulations
|
WO2008154927A1
(en)
*
|
2007-06-21 |
2008-12-24 |
Genmab A/S |
Novel methods for treating egfr-associated tumors
|
CN101896503B
(zh)
|
2007-08-14 |
2018-05-22 |
路德维格癌症研究所有限公司 |
靶向egf受体的单克隆抗体175及其衍生物和用途
|
CA2699944C
(en)
|
2007-09-21 |
2017-11-14 |
The Regents Of The University Of California |
Targeted interferon demonstrates potent apoptotic and anti-tumor activities
|
ATE513856T1
(de)
|
2008-04-11 |
2011-07-15 |
Emergent Product Dev Seattle |
Cd37-immuntherapeutikum und kombination mit bifunktionellem chemotherapeutikum davon
|
AU2009241589B2
(en)
|
2008-04-29 |
2013-10-10 |
Abbvie Inc. |
Dual variable domain immunoglobulins and uses thereof
|
MX2010013236A
(es)
|
2008-06-03 |
2011-02-24 |
Abbott Lab |
Inmunoglobulinas de dominio variable doble y usos de las mismas.
|
EP3002299A1
(en)
|
2008-06-03 |
2016-04-06 |
AbbVie Inc. |
Dual variable domain immunoglobulins and uses thereof
|
MX2010014574A
(es)
|
2008-07-08 |
2011-04-27 |
Abbott Lab |
Inmunoglobulinas de dominio variable dual para prostaglandina e2 y usos de las mismas.
|
CN102159540B
(zh)
|
2008-07-21 |
2015-08-12 |
布赖汉姆妇女医院 |
与合成的β-1,6葡糖胺寡糖相关的方法和组合物
|
KR101108642B1
(ko)
*
|
2009-09-29 |
2012-02-09 |
주식회사 녹십자 |
표피 성장 인자 수용체에 특이적으로 결합하는 항체
|
US8716450B2
(en)
|
2009-10-15 |
2014-05-06 |
Abbvie Inc. |
Dual variable domain immunoglobulins and uses thereof
|
UY32979A
(es)
|
2009-10-28 |
2011-02-28 |
Abbott Lab |
Inmunoglobulinas con dominio variable dual y usos de las mismas
|
US20120282274A1
(en)
*
|
2009-11-20 |
2012-11-08 |
Northshore University Health System Research Institute |
Targeting of the c-terminal segment of c.difficile toxin b for improved clinical diagnosis, prevention, and treatment
|
CN107337734A
(zh)
|
2009-12-04 |
2017-11-10 |
弗·哈夫曼-拉罗切有限公司 |
多特异性抗体、抗体类似物、组合物和方法
|
CN102167743B
(zh)
*
|
2010-02-25 |
2014-05-14 |
上海百迈博制药有限公司 |
一种全人源抗egfr单克隆抗体、其制备方法及用途
|
DK2560683T4
(da)
|
2010-04-23 |
2022-08-29 |
Hoffmann La Roche |
Fremstilling af heteromultimeriske proteiner
|
WO2011152525A1
(ja)
*
|
2010-06-04 |
2011-12-08 |
東亞合成株式会社 |
抗体およびその利用
|
RU2013109275A
(ru)
|
2010-08-03 |
2014-09-10 |
Эббви Инк. |
Иммуноглобулины с двумя вариабельными доменами и их применение
|
KR20130139884A
(ko)
|
2010-08-26 |
2013-12-23 |
애브비 인코포레이티드 |
이원 가변 도메인 면역글로불린 및 이의 용도
|
KR101273918B1
(ko)
*
|
2010-09-17 |
2013-06-13 |
강원대학교산학협력단 |
인간 항-상피세포성 성장인자수용체 Fab 항체 및 이를 포함하는 종양 치료용 약학 조성물
|
US9238690B2
(en)
|
2010-10-29 |
2016-01-19 |
Immunogen, Inc. |
Non-antagonistic EGFR-binding molecules and immunoconjugates thereof
|
EA201390472A1
(ru)
|
2010-10-29 |
2014-02-28 |
Иммьюноджен, Инк. |
Новые молекулы, связывающиеся с egfr, и их иммуноконъюгаты
|
US10689447B2
(en)
|
2011-02-04 |
2020-06-23 |
Genentech, Inc. |
Fc variants and methods for their production
|
WO2012106587A1
(en)
|
2011-02-04 |
2012-08-09 |
Genentech, Inc. |
Fc VARIANTS AND METHODS FOR THEIR PRODUCTION
|
EP3138581B1
(en)
|
2011-03-17 |
2019-01-02 |
The University of Birmingham |
Re-directed immunotherapy
|
WO2013006706A1
(en)
|
2011-07-05 |
2013-01-10 |
Bioasis Technologies Inc. |
P97-antibody conjugates and methods of use
|
CA2842492A1
(en)
|
2011-08-05 |
2013-02-14 |
Bioasis Technologies, Inc. |
P97 fragments with transfer activity
|
EP2760893B1
(en)
|
2011-09-30 |
2018-09-12 |
Regeneron Pharmaceuticals, Inc. |
Anti-erbb3 antibodies and uses thereof
|
US9273143B2
(en)
|
2011-09-30 |
2016-03-01 |
Regeneron Pharmaceuticals, Inc. |
Methods and compositions comprising a combination of an anti-ErbB3 antibody and an anti-EGFR antibody
|
KR102037541B1
(ko)
|
2011-10-28 |
2019-10-29 |
테바 파마슈티컬즈 오스트레일리아 피티와이 엘티디 |
폴리펩티드 구축물 및 이의 용도
|
RU2014121820A
(ru)
|
2011-11-21 |
2015-12-27 |
Иммьюноджен, Инк. |
Способ лечения опухолей, устойчивых к анти-egfr терапиям, с помощью конъюгата антитела egfr с цитотоксическим средством
|
TW201333035A
(zh)
|
2011-12-30 |
2013-08-16 |
Abbvie Inc |
針對il-13及/或il-17之雙特異性結合蛋白
|
US9872904B2
(en)
|
2012-03-21 |
2018-01-23 |
Fraunhofer-Gesellschaft Zur Foerderung Der Angewandten Forschung E.V. |
Photoimmunoconjugates for use in photodynamic therapy
|
CN104918956A
(zh)
|
2012-05-17 |
2015-09-16 |
索伦托治疗有限公司 |
与egfr结合的抗原结合蛋白
|
TWI641619B
(zh)
|
2012-06-25 |
2018-11-21 |
美商再生元醫藥公司 |
抗-egfr抗體及其用途
|
ES2647082T3
(es)
|
2012-07-31 |
2017-12-19 |
Bioasis Technologies Inc |
Proteínas desfosforiladas de la enfermedad de depósito lisosómico y métodos de uso de las mismas
|
RU2017137740A
(ru)
|
2012-11-01 |
2019-02-11 |
Эббви Инк. |
Анти-vegf/dll4-иммуноглобулины с двойными вариабельными доменами и их применения
|
JP6586412B2
(ja)
|
2013-03-13 |
2019-10-02 |
バイオアシス テクノロジーズ インコーポレイテッド |
p97のフラグメントおよびその使用
|
BR112015023797A2
(pt)
|
2013-03-15 |
2017-10-24 |
Abbvie Inc |
proteínas de ligação de especificidade dupla dirigidas contra il-1b e/ou il-17
|
US11117975B2
(en)
|
2013-04-29 |
2021-09-14 |
Teva Pharmaceuticals Australia Pty Ltd |
Anti-CD38 antibodies and fusions to attenuated interferon alpha-2B
|
FI3677591T3
(fi)
|
2013-04-29 |
2023-04-03 |
Teva Pharmaceuticals Australia Pty Ltd |
Anti-cd38-vasta-aineet ja fuusiot heikennetylle interferonille alfa-2b
|
WO2015031673A2
(en)
|
2013-08-28 |
2015-03-05 |
Bioasis Technologies Inc. |
Cns-targeted conjugates having modified fc regions and methods of use thereof
|
AU2015210612B2
(en)
|
2014-02-03 |
2020-04-09 |
Bioasis Technologies Inc. |
P97 fusion proteins
|
ES2762672T3
(es)
|
2014-02-19 |
2020-05-25 |
Bioasis Technologies Inc |
Proteínas de fusión de P97-IDS
|
US10058619B2
(en)
|
2014-05-01 |
2018-08-28 |
Bioasis Technologies, Inc. |
P97-polynucleotide conjugates
|
UA119352C2
(uk)
|
2014-05-01 |
2019-06-10 |
Тева Фармасьютикалз Острейліа Пті Лтд |
Комбінація леналідоміду або помалідоміду і конструкції анти-cd38 антитіло-атенуйований інтерферон альфа-2b та спосіб лікування суб'єкта, який має cd38-експресуючу пухлину
|
CN106456768B
(zh)
|
2014-06-13 |
2019-12-03 |
腾博龙公司 |
含有抗egfr1抗体的缀合物
|
UA125637C2
(uk)
|
2014-10-29 |
2022-05-11 |
Тева Фармасьютікалз Острейліа Пті Лтд |
ЗЛИТИЙ ПОЛІПЕПТИД ІНТЕРФЕРОНУ <font face="Symbol">a2</font>b
|
US10093733B2
(en)
|
2014-12-11 |
2018-10-09 |
Abbvie Inc. |
LRP-8 binding dual variable domain immunoglobulin proteins
|
TW201710286A
(zh)
|
2015-06-15 |
2017-03-16 |
艾伯維有限公司 |
抗vegf、pdgf及/或其受體之結合蛋白
|
CA2999138C
(en)
|
2015-09-21 |
2024-05-21 |
Aptevo Research And Development Llc |
Cd3 binding polypeptides
|
IL263102B2
(en)
|
2016-05-20 |
2023-11-01 |
Harpoon Therapeutics Inc |
A serum albumin-binding protein with a single site
|
US11623958B2
(en)
|
2016-05-20 |
2023-04-11 |
Harpoon Therapeutics, Inc. |
Single chain variable fragment CD3 binding proteins
|
EP3487522A4
(en)
|
2016-07-19 |
2020-04-01 |
Teva Pharmaceuticals Australia Pty Ltd |
ANTI-CD47 COMBINATION THERAPY
|
CN110300603B
(zh)
*
|
2017-02-14 |
2023-04-14 |
亘喜生物科技(上海)有限公司 |
Cd47-car-t细胞
|
EP3589662A4
(en)
|
2017-02-28 |
2020-12-30 |
Harpoon Therapeutics, Inc. |
INDUCTIBLE MONOVALENT ANTIGBINDING PROTEIN
|
CN110891974B
(zh)
|
2017-05-12 |
2021-08-06 |
哈普恩治疗公司 |
间皮素结合蛋白质
|
US10927180B2
(en)
|
2017-10-13 |
2021-02-23 |
Harpoon Therapeutics, Inc. |
B cell maturation antigen binding proteins
|
CN109879964B
(zh)
*
|
2017-12-06 |
2022-08-05 |
北京科立思维生物科技有限公司 |
抗egfr单链抗体、抗pd1单链抗体及融合蛋白
|
WO2019195959A1
(en)
|
2018-04-08 |
2019-10-17 |
Cothera Biosciences, Inc. |
Combination therapy for cancers with braf mutation
|
MX2021003554A
(es)
|
2018-09-25 |
2021-05-27 |
Harpoon Therapeutics Inc |
Proteinas de union a dll3 y metodos de uso.
|
CN113226472A
(zh)
|
2018-12-17 |
2021-08-06 |
雷维托普有限公司 |
双免疫细胞衔接物
|
US20230183371A1
(en)
*
|
2020-04-30 |
2023-06-15 |
Board Of Regents, The University Of Texas System |
Anti-cd79b antibodies and chimeric antigen receptors and methods of use thereof
|
CA3128035A1
(en)
|
2020-08-13 |
2022-02-13 |
Bioasis Technologies, Inc. |
Combination therapies for delivery across the blood brain barrier
|
WO2022074206A1
(en)
|
2020-10-08 |
2022-04-14 |
Affimed Gmbh |
Trispecific binders
|
AU2022320948A1
(en)
|
2021-07-30 |
2024-01-18 |
Affimed Gmbh |
Duplexbodies
|
AR127568A1
(es)
|
2021-11-03 |
2024-02-07 |
Affimed Gmbh |
Ligandos biespecíficos de cd16a
|